Los Angeles Capital Management’s Immunovant IMVT Stock Holding History

Los Angeles Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$344K	Buy	8,930 +6,913	+343%	+$211K	﹤0.01%	1015
2026 Q1	$50.1K	Buy	2,017 +1,713	+563%	+$44.4K	﹤0.01%	1498
2025 Q4	$7.54K	Buy	+304	New	+$6.78K	﹤0.01%	2174
2024 Q3	–	Sell	-10,026	Closed	-$265K	–	1224
2024 Q2	$265K	Sell	10,026 -4,345	-30%	-$124K	﹤0.01%	1055
2024 Q1	$464K	Buy	14,371 +9,335	+185%	+$341K	﹤0.01%	894
2023 Q4	$212K	Buy	+5,036	New	+$185K	﹤0.01%	1083
2021 Q2	–	Sell	-13,880	Closed	-$223K	–	1604
2021 Q1	$223K	Buy	+13,880	New	+$366K	﹤0.01%	1513

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Los Angeles Capital Management's IMVT Position: Q2 2026 in Review

Los Angeles Capital Management increased its Immunovant (IMVT) stake by 343% in Q2 2026, buying an estimated $211K and bringing the position to 8,930 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Los Angeles Capital Management first reported a position in IMVT in Q1 2021 and has held it in 7 quarters since. The position peaked at $464K in Q1 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Los Angeles Capital Management held 8,930 shares of Immunovant worth $344K as of Q2 2026.
Los Angeles Capital Management bought 6,913 Immunovant shares in Q2 2026, an estimated $211K.
Immunovant made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1015 holding.
Los Angeles Capital Management first reported a position in Immunovant in Q1 2021 and has held it in 7 quarters since.
Los Angeles Capital Management's Immunovant position peaked at $464K in Q1 2024.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.